CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime–Avibactam And Aztreonam–Avibactam

• Main Authors: Zou H, Xiong SJ, Lin QX, Wu ML, Niu SQ, Huang SF
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-09-01
• Series: Infection and Drug Resistance
• Subjects: Aztreonam–avibactam; carbapenemase-producing carbapenem-resistant Enterobacteriaceae; carbapenem-resistant Enterobacteriaceae bacteremia; ceftazidime–avibactam; resistance mechanism stratification
• Online Access: https://www.dovepress.com/cp-crenon-cp-cre-stratification-and-cre-resistance-mechanism-determina-peer-reviewed-article-IDR
• ISSN: 1178-6973

Hua Zou,1,* Sen-Jie Xiong,2,* Qiu-Xia Lin,1,* Meng-Lu Wu,1 Si-Qiang Niu,1 Shi-Feng Huang1 1Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People’s Republic of China*These authors contributed equally to this workCorrespondence: Si-Qiang Niu; Shifeng HuangDepartment of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No. 1 Friendship Road, Yuzhong District, Chongqing 400016, People’s Republic of ChinaTel [phone]; Tel [phone]Fax [phone]Email [e-mail]; [e-mail]: This observational study aimed to identify the independent risk factors for both the acquisition and mortality of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) bacteremia and further assess the in vitro antimicrobial activities of ceftazidime–avibactam (CAZ/AVI) and aztreonam–avibactam (ATM/AVI) against recent CRE bacteremic isolates.Patients and methods: This observational study was conducted to reveal the risk factors and mortality rate for CP-CRE bacteremia between 2012 and 2018 and also evaluate the in vitro antimicrobial activities of CAZ/AVI and ATM/AVI against recent CRE bacteremic isolates from 2016 to 2018.Results: A total of 81 non-repetitive isolates were collected from 2012 to 2018, with 67.90% (55/81) being CP-CRE. Old age (P = 0.01), transfusion [odds ratio (OR): 17.19; 95% CI: 3.15–93.72; P = 0.001], longer ICU stay (P = 0.02), cancer (OR: 15.91; 95% CI: 3.56–71.37; P < 0.001), and previous carbapenem exposure (OR: 27.86; 95% CI: 5.03–154.19; P = 0.001) were identified as independent risk factors for the acquisition of CP-CRE bacteremia compared with the ESBL bacteremia. The in vitro antimicrobial activities of CAZ/AVI and ATM/AVI against the CRE bacteremic isolates from 2016 to 2018 showed a respective susceptibility rate of 70.68% (41/58) and 100.00% (58/58).Conclusion: The findings indicated that both CP-CRE/non-CP-CRE stratification and CRE resistance mechanism determination were necessary for better guiding the clinical management of CRE bacteremia: ATM/AVI probably works with both non-CP-CRE and CP-CRE bacteremia, even the most notorious double-carbapenemase producer with porin loss/deficiency, whereas CAZ/AVI works with most of the non-CP-CRE and KPC-producers in the region.Keywords: aztreonam–avibactam, carbapenemase-producing carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae bacteremia, ceftazidime–avibactam